Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice

Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: Implication of cilostazol for diabetes mellitus-induced dementia

(2015) Kyoung Ja Kwon et al.   NEUROBIOLOGY OF DISEASE

Population Pharmacodynamic Modeling of Exenatide After 2-Week Treatment in STZ/NA Diabetic Rats

(2013) Ting Chen et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A Functional Role for CREB as a Positive Regulator of Memory Formation and LTP

(2013) Satoshi Kida   Experimental Neurobiology

Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity

(2011) Nian Gong et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

(2010) D. W. Porter et al.   DIABETES OBESITY & METABOLISM

The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test

(2010) Ruben Isacson et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

(2010) V A Gault et al.   INTERNATIONAL JOURNAL OF OBESITY

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

(2010) X.H. Wang et al.   NEUROSCIENCE

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

(2010) Scott R Drab   PHARMACOTHERAPY

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

(2009) Talib Abbas et al.   BEHAVIOURAL BRAIN RESEARCH

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

The influences of juvenile diabetes on memory and hippocampal plasticity in rats: Improving effects of glucagon-like peptide-1

(2009) Takashi Iwai et al.   NEUROSCIENCE RESEARCH

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

(2008) Victor A. Gault et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats

(2008) Alexis M. Stranahan et al.   HIPPOCAMPUS

Glucagon-like Peptide-1 (GLP-1) Diminishes Neuronal Degeneration and Death Caused by NGF Deprivation by Suppressing Bim Induction

(2008) Subhas C. Biswas et al.   NEUROCHEMICAL RESEARCH

Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42)

(2008) Zhenxia Qin et al.   NEUROSCIENCE LETTERS

Synaptic activity-responsive element in the Arc/Arg3.1 promoter essential for synapse-to-nucleus signaling in activated neurons

(2008) T. Kawashima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA